News|Videos|October 10, 2023
EP. 11: Setting Treatment Expectations for Patients with OAB Receiving Third-Line Therapies
Focused discussion on effectively communicating expectations for third-line therapies with patients being treated for OAB.
Advertisement
Please see full
Sponsored by AbbVie US Medical Affairs
Episodes in this series
This content is intended for US/PR Healthcare Professionals.
The Medical Affairs department of AbbVie Inc. is the sole author and copyright owner of this presentation and has paid Urology Times to host this presentation. AbbVie is solely responsible for all written and oral content within this presentation. © 2023 AbbVie Inc. All rights reserved.
Advertisement
Related to this article
Kiran Sury, MD, discusses patient selection, durability, and adverse events with ProACT for male stress urinary incontinence.
Advertisement
Advertisement
Trending on Urology Times
1
Treatment interruptions in prostate cancer: Balancing PSA kinetics and quality of life
2
FDA approves durvalumab plus enfortumab vedotin for cisplatin-ineligible MIBC
3
FDA grants breakthrough therapy designation to 64Cu-SAR-bisPSMA for recurrent prostate cancer imaging
4
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
5